Skip to main content
. 2022 Jul 14;44(1):211–220. doi: 10.1038/s41401-022-00945-z

Fig. 3. HAT1 is required for the aspirin-mediated decrease of PGAM1 Succ levels and PGAM1 enzymatic activities.

Fig. 3

a KEGG pathway analysis for RNA-seq in HepG2 cells treated with 4 mM aspirin. b The volcano analysis of RNA-seq of 4 mM aspirin-treated HepG2 cells. c The expression of HAT1 in RNA-seq of 4 mM aspirin-treated HepG2 cells. d The expression levels of HAT1 were examined by Western blot analysis in HepG2 and Huh7 cells treated with DMSO, 2 mM, and 4 mM aspirin for 48 h. e IP assays were performed by using PGAM1 antibody in HepG2 and Huh7 cells treated with DMSO, 4 mM aspirin, both 4 mM aspirin and 2 μg HAT1-pCMV-3Tag-1A for 48 h, respectively. The levels of PGAM1 succinylation and HAT1 were detected by Western blot analysis. f The activities of PGAM1 in HepG2 and Huh7 cells treated with DMSO, 4 mM aspirin, co-treatment of 4 mM aspirin, and 2 μg HAT1-pCMV-3Tag-1A for 48 h were measured by ELISA, respectively. g, h The levels of 3-PG and 2-PG in HepG2 and Huh7 cells treated with DMSO, 4 mM aspirin, both 4 mM aspirin and 2 μg HAT1-pCMV-3Tag-1A for 48 h were examined by ELISA, respectively. The mean ± SD of at least three experiments is shown. Statistically significant differences are indicated as follows: Student‘s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.